Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar
Shots:
- Genentech filed a complaint in the Eastern District of Texas alleging that the proposed biosimilar to Avastin (bevacizumab) product infringes 10 US patents
- Genentech alleges that Centus and partners failed to disclose sufficient information about the proposed biosimilar to enable Genentech to do a sufficient analysis of potential patent infringements
- Centus has a BLA under review with the FDA for the bevacizumab biosimilar candidate FKB238- and the company has filed a notice of intent to commercialize the agent
Click here to read full press release/ article | Ref: BigMoleculeWatch | Image: Genentech
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
